Evidence map›Paper›PMID 42308049›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Non-cell-autonomous mechanisms of tumor initiation and relapse by chromosomal instability.

Simona J A Lafirenze, Bastiaan van Gerwen, Ajit I Quirindongo, Natasja Costermans, Aniek Janssen, Banafsheh Etemad, Pim Toonen, Marco A D Louro, Wilma H M Hoevenaar, Sameh Youssef and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Non-cell-autonomous mechanisms of tumor initiation and relapse by chromosomal instability.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Simona J A Lafirenze *Hubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.ORCID 0009-0005-7762-2187
Bastiaan van Gerwen *Hubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
Ajit I QuirindongoHubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.ORCID 0009-0008-5138-9200
Natasja CostermansHubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
Aniek JanssenCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.ORCID 0000-0001-6731-6657
Banafsheh EtemadHubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
Pim ToonenHubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
Marco A D LouroHubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.ORCID 0000-0002-7023-799X
Wilma H M HoevenaarHubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
Sameh YoussefDepartment of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht 3584 CL, The Netherlands.
Alain de BruinDepartment of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht 3584 CL, The Netherlands.ORCID 0000-0001-8579-2649
Lodewijk A A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.ORCID 0000-0003-1341-8994
Nannette Jelluma *Hubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
Geert J P L Kops *Hubrecht Institute 3584 CT Koninklijke Nederlandse Akademie van Wetenschappen 1011 JV and University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.ORCID 0000-0003-3555-5295

Funding

EC | European Research Council (ERC) ERC-SyG 855158KWF Kankerbestrijding (KWF) HUBR-2012-5321KWF Kankerbestrijding (KWF) HUBR-2012-551KWF Kankerbestrijding (KWF) KWF 10126
6 · The paper itself

Abstract

Chromosomal instability (CIN) is a hallmark of cancer, and a primary cause of genetic heterogeneity in tumors. Depending on the degree of CIN and the affected tissue, CIN can promote or suppress tumor formation, and high CIN induction has been proposed as a therapeutic strategy. How CIN achieves these effects is unclear. Here we use a conditional mouse model of graded CIN in combination with longitudinal monitoring of DMBA/TPA-initiated skin tumors to show that low CIN increases the frequency of skin tumor initiation, while higher CIN accelerates tumor onset and growth rates. Strikingly, gene recombination analysis of the tumors reveals that upon high CIN induction the fast-growing tumors originate from rare low CIN cells, suggesting a strong non-cell-autonomous effect of high CIN. Gene expression analysis and immunohistochemistry show that high CIN causes epidermal hyperplasia, immune evasion, and a regenerative response that stimulates low CIN tumor growth beyond what is achieved by induction of low CIN alone. Such cell-extrinsic effects may be a common mechanism of tumor formation by CIN, as we observe it also in CIN-induced tumors of the intestine, breast, and mesentery. When high CIN is induced in established skin tumors, mimicking CIN-based therapy, tumors regress but relapse quickly. Relapsed tumors, too, arose from rare low CIN cells. Our findings have implications for our understanding of the contributions of CIN to cancer initiation and progression and give caution to the rationale for CIN therapies.

Indexed as

CarcinogenesisChromosomal InstabilityNeoplasm Recurrence, LocalSkin Neoplasms9,10-Dimethyl-1,2-benzanthraceneAnimalsMice9,10-Dimethyl-1,2-benzanthracenecancerchromosomal instabilityinflammationnon-cell autonomous mechanism

Identifiers

PMID42308049
PMCPMC13291667

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.